PHILADELPHIA, Aug. 12, 2011 /PRNewswire/ — Echo Therapeutics,
Inc. (Nasdaq:
ECTE), a company developing its needle-free Symphony™
tCGM System as a non-invasive, wireless, transdermal continuous
glucose monitoring (tCGM) system and its Prelude™ SkinPrep
System for transdermal drug delivery, today announced results for
the period ended June 30, 2011. Echo’s Quarterly Report on
Form 10-Q is available through Echo’s website at www.echotx.com.
Recent Corporate Highlights:
In May 2011, Christopher P. Schnittker, CPA, joined Echo
Therapeutics as its Chief Financial Officer. Mr. Schnittker
is a senior executive with more than twenty years of financial
management, reporting and corporate governance experience in the
biotechnology and pharmaceutical industries. In May 2011,
Echo’s corporate headquarters relocated from Franklin, MA to
Philadelphia, PA in response to Echo’s growing and evolving
business. Echo continues to expand its Franklin office as the
operations hub for its engineering and product development
personnel. Echo and its products have been featured in the press
several times. Echo Therapeutics’ needle-free Symphony tCGM
System was featured in a
story in the Philadelphia Inquirer on May 9, 2011 entitled “
Former Surgeon Developing Needle-Free Technology.” A
podcast of MassDevice’s
interview w
‘/>”/>
SOURCE